Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Sage Therapeutics (NASDAQ:SAGE) and lowers the price target from $49 to $20.
August 09, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has lowered the price target for Sage Therapeutics from $49 to $20 while maintaining an Equal-Weight rating.
The lowering of the price target by a major financial institution like Morgan Stanley indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100